Novice Interpreters, American Sign Language Proficiency, and the National Interpreter Certification Performance Exam

More than 40 years after American Sign Language (ASL) and interpreter education were first offered as programs of study in higher education, little is known about the level of ASL proficiency of graduates from baccalaureate degree programs in interpreting and what level of ASL proficiency may be associated with passing the performance portion of the National Interpreter Certification (NIC) examination. With this in mind, we posed three questions: 1) What is the distribution of ASL Proficiency Interview (ASLPI) ratings of a national sample of novice interpreters relatively near the time of graduation from baccalaureate degree programs in interpreting? 2) What is the distribution of ASLPI ratings of a national sample of novice interpreters relatively near the time of taking the NIC Performance Exam? 3) What is the relationship between ASLPI ratings and passing/not passing the NIC Performance Exam? Results showed that relatively closer to IEP graduation (N = 134), about 56% of ASLPI proficiency levels were at or below Level 2+ and 44% were at or above Level 3. For ASLPI proficiency levels obtained relatively closer to taking the NIC Performance Exam (N = 154), about 30% were at or below Level 2+ and 70% of ratings were at or above Level 3. Results showed that all those who passed the NIC Performance Exam, and who had a rating for the ASLPI taken relatively closer to taking the NIC Performance Exam (N = 27), obtained an ASLPI proficiency level of 3 or higher. However, it is important to note that approximately 75% of participants who obtained a proficiency level of 3 or higher did not pass the NIC Performance Exam the first time they took it. Additionally, the higher the ASLPI level, the higher the proportion of people passing the NIC Performance Exam. This study has implications for further research regarding ASL proficiency for students entering and exiting IEPs and preparing for national credentialing

Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson’s Disease Care Pathway: A Healthcare Improvement Initiative

Background: There is significant unmet need for effective and efficiently delivered care for people with Parkinson’s disease (PwP). We undertook a service improvement initiative to co-develop and implement a new care pathway, Home Based Care (HBC), based on supported self-management, remote monitoring and the ability to trigger a healthcare contact when needed. Objective: To evaluate feasibility, acceptability and safety of Home Based Care. Methods: We evaluated data from the first 100 patients on HBC for 6 months. Patient monitoring, performed at baseline and 6-monthly, comprised motor (MDS-UPDRS II and accelerometer), non-motor (NMSQ, PDSS-2, HADS) and quality of life (PDQ) measures. Care quality was audited against Parkinson’s UK national audit standards. Process measures captured feasibility. Acceptability was assessed using a mixed-methods approach comprising questionnaires and semi-structured interviews. Results: Between October 2019 and January 2021, 108 PwP were enrolled onto HBC, with data from 100 being available at 6 months. Over 90% of all questionnaires were returned, 97% were complete or had < 3 missing items. Reporting and communications occurred within agreed timeframes. Compared with baseline, after 6m on HBC, PD symptoms were stable; more PwP felt listened to (90% vs. 79%) and able to seek help (79% vs. 68%). HBC met 93% of national audit criteria. Key themes from the interviews included autonomy and empowerment. Conclusions: We have demonstrated acceptability, feasibility and safety of our novel remotely delivered Parkinson’s care pathway. Ensuring scalability will widen its reach and realize its benefits for underserved communities, enabling formal comparisons with standard care and cost-effectiveness evaluation

Foot-and-Mouth Disease Virus Serotype A in Egypt

We describe the characterization of a foot-and-mouth disease (FMD) serotype A virus responsible for recent outbreaks of disease in Egypt. Phylogenetic analysis of VP1 nucleotide sequences demonstrated a close relationship to recent FMD virus isolates from East Africa, rather than to viruses currently circulating in the Middle East

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.

Genomic alterations in cancer cells result in vulnerabilities that clinicians can exploit using molecularly targeted drugs, guided by knowledge of the tumour genotype. However, the selective activity of these drugs exerts an evolutionary pressure on cancers that can result in the outgrowth of resistant clones. Use of rational drug combinations can overcome resistance to targeted drugs, but resistance may eventually develop to combinatorial therapies. We selected MAPK- and PI3K-pathway inhibition in colorectal cancer as a model system to dissect out mechanisms of resistance. We focused on these signalling pathways because they are frequently activated in colorectal tumours, have well-characterised mutations and are clinically relevant. By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we observe a synergistic inhibition of growth in almost all cell lines. Cells with KRAS mutations are less sensitive to PI3K inhibition, but are particularly sensitive to the combined treatment. Colorectal cancer cell lines with inherent or acquired resistance to monotherapy do not show a synergistic response to the combination treatment. Cells that acquire resistance to an MEK-PI3K inhibitor combination treatment still respond to an ERK-PI3K inhibitor regimen, but subsequently also acquire resistance to this combination treatment. Importantly, the mechanisms of resistance to MEK and PI3K inhibitors observed, MEK1/2 mutation or loss of PTEN, are similar to those detected in the clinic. ERK inhibitors may have clinical utility in overcoming resistance to MEK inhibitor regimes; however, we find a recurrent active site mutation of ERK2 that drives resistance to ERK inhibitors in mono- or combined regimens, suggesting that resistance will remain a hurdle. Importantly, we find that the addition of low concentrations of the BCL2-family inhibitor navitoclax to the MEK-PI3K inhibitor regimen improves the synergistic interaction and blocks the acquisition of resistance

The biometric potential of transient otoacoustic emissions

Whilst the hearing capabilities of the ear are well known and extensively studied, less well known is the fact that the ear can produce sounds. These faint sounds are called otoacoustic emissions and are an involuntary feature of the biomechanical system employed to hear low amplitude sounds. Several distinct types of emission are known; of these, one particular type, transient otoacoustic emissions (TEOAEs), shows potential as a biometric. This paper graphically presents examples of TEOAEs to demonstrate the specificity of TEOAEs to an individual and their stability over a six month period of time. Several large datasets (760 and 561 subjects) and a smaller dataset are numerically analysed to classify individuals and quantify permanence over six months. It was discovered that a high level of classification performance can be obtained using the raw time-pressure data without transformation